Lintuzumab  (Synonyms: SGN-33; HuM-195; GLK-33 Antibody)

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Lintuzumab (5 μg/mL, 0.1-2 h) induces phosphorylation of CD33 and recruitment of Shp-1 phosphatase inHL60 cells^[2].
Lintuzumab (2500 ng/mL) significantly decreases the production of tumorigenic growth factors including IL-8, MCP-1, IP-10 and RANTES in KG-1 cells^[2].
Lintuzumab (0.1 ng/mL-10 μg/mL) exerts multiple effector functions including the ability to mediate ADCC and ADCP in AML cell lines^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lintuzumab (3-30 mg/kg, i.v., 4 doses) significantly improves the survival of HL-60 xenograft mice compared to the control^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

945  [NCBI]

P20138

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.24 kDa

166089-32-3

Liquid

Colorless to light yellow

[Lintuzumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Siglec-3/CD33 Protein, Human can bind Lintuzumab. The EC₅₀ for this effect is 1.206 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ THP-1 cells with Lintuzumab (HY-P9983, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.

• [1]. Lintuzumab

  [2]. Sutherland, M. K., et al., (2009). Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs, 1(5), 481–490.  [Content Brief]